Cerebrospinal Fluid Haptoglobin (Hp) Levels are elevated in MS patients with progressive disease (P5.213)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To investigate the role of haptoglobin (Hp) in MS. BACKGROUND: Hp is an acute phase protein, with known antioxidant and anti-inflammatory activity. Hp is also involved in regulation of the immune system. CSF Hp is elevated in neuromyelitis optica (NMO). In addition, certain haptoglobin phenotypes are specifically associated with different diseases. Here, we investigated CSF levels of Hp and determined Hp phenotypic expression in plasma obtained from clinically definite MS patients with relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS) disease. DESIGN/METHODS: CSF Hp levels were determined by ELISA in RRMS (N=28), SPMS (N=101), and PPMS (N=26) patients. In 58 MS patients, paired CSF and serum Hp levels as well as corresponding albumin values were measured to determine CNS specificity. Hp phenotypes (Hp1-1, Hp2-1, Hp2-2) in plasma were detected by Western blot. To further validate the CNS specific Hp response, we investigated Hp immunostaining in MS brain tissue. RESULTS: We found significantly elevated CSF Hp levels in progressive MS compared to RRMS with no such differences observed in the CSF albumin indexes. No correlation was seen with plasma levels suggesting that this is a CNS specific response. Levels of CSF Hp were similar in SPMS and PPMS. In human brain MS lesions, macrophage and reactive astrocytes are positive for Hp and these findings are not seen in normal appearing white matter again suggesting a CNS based pathogenesis for the elevated CSF Hp levels. The plasma Hp2-2 phenotype was over represented in PPMS patients as compared to SPMS or RRMS patients. CONCLUSIONS: CSF Hp concentration was increased in progressive type MS patients when compared with RRMS patients. The elevated haptoglobin in CSF appears to correlate with CNS specific events. Hp2-2 phenotype in PPMS patients may suggest a vulnerability to oxidative stress. Study Supported by: Shubert Foundation
Disclosure: Dr. Ulloa has nothing to disclose. Dr. Alahiri has nothing to disclose. Dr. Liu has nothing to disclose. Dr. Sadiq has nothing to disclose.
Wednesday, April 22 2015, 2:00 pm-6:30 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.